Titan Pharma Inc (TTNP) 0.7000 $TTNP
TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach of Fiduciary Duty
Business Wire - Wed Apr 08, 7:21AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals, Inc. (OTC:TTNP) ("Titan Pharmaceuticals" or the "Company"
.
Titan Pharmaceuticals' (TTNP) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 2:58PM CDT
Stock to Watch: Titan Pharmaceuticals Up 5.2% (TTNP)
Comtex SmarTrend(R) - Tue Mar 31, 10:17AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.2% to $0.71 on 1.1x average daily volume. Thus far today, Titan Pharmaceuticals has traded 488,000 shares, vs. average volume of 432,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.3%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.
Titan Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Tue Mar 31, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the fourth quarter and year ended December 31, 2014.
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 25, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Wednesday, April 1, 2014 to discuss the company's financial results as of December 31, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the fourth quarter and full year financial results will be included in a press release to be issued prior to the call.
Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.22 (unch), GSAT: 3.07 (+0.09)
Titan Pharmaceuticals to Present at 27th Annual ROTH Conference
Marketwired - Tue Mar 03, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that Titan President Sunil Bhonsle will present at the 27th annual ROTH Conference on Monday, March 9 at 9:30 a.m. PT at The Ritz-Carlton in Laguna Niguel, Calif.
Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 6.3% (TTNP)
Comtex SmarTrend(R) - Mon Mar 02, 10:08AM CST
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 6.3% to $0.68 on 1.4x average daily volume. Thus far today, Titan Pharmaceuticals has traded 732,000 shares, vs. average volume of 509,000 shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.7%) and outperformed the S&P 500 (6.3% to the S&P's 0.4%) during today's trading.
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.94 (+0.80), ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25), XNPT: 7.60 (+0.17), IPXL: 50.68 (-0.43), ABBV: 62.00 (+1.68), TEVA: 66.37 (-0.77), SNY: 52.35 (+0.48), PRTA: 36.91 (+0.52)
Roth Capital's 4 Reasons To Be Bullish On Titan Pharmaceuticals
TipRanks - at Seeking Alpha - Mon Jan 26, 1:28PM CST
By Sarah Roden Titan Pharmaceuticals ( OTCQB:TTNP ) is a biomedical pharmaceutical company most known for its flagship drug, Probuphine, used to treat opioid addiction. Probuphine has proved to be effective in two clinical studies and one safety...
Titan Pharmaceuticals to Present at 8th Annual OneMedForum
Marketwired - Tue Jan 06, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 8th annual OneMedForum taking place on January 12-13, 2015 in San Francisco. The presentation is scheduled for Jan. 12 at 11 a.m. in the Public Company Track Room, Marriott Marquis, San Francisco, California.
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 50.68 (-0.43), ADMS: 17.94 (+0.80), TEVA: 66.37 (-0.77), ACOR: 34.46 (+0.61), PRTA: 36.91 (+0.52), NDRM: 13.93 (-0.25)
Titan Pharmaceuticals to Present at LD Micro Conference
Marketwired - Mon Dec 01, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 8:30 a.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif.
Enrollment complete in Probuphine Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:03AM CST
Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence
Marketwired - Thu Nov 20, 5:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.
Titan Pharmaceuticals EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:38AM CST
Titan Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Thu Nov 13, 6:02AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the third quarter ended Sept. 30, 2014.
Titan Pharmaceuticals Appoints Two New Board Members
Marketwired - Tue Nov 11, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
CRIS: 2.80 (-0.01)
Titan Pharma reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:12AM CST
TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach of Fiduciary Duty
Business Wire - Wed Apr 08, 7:21AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals, Inc. (OTC:TTNP) ("Titan Pharmaceuticals" or the "Company"
. Titan Pharmaceuticals' (TTNP) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 2:58PM CDT
Stock to Watch: Titan Pharmaceuticals Up 5.2% (TTNP)
Comtex SmarTrend(R) - Tue Mar 31, 10:17AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.2% to $0.71 on 1.1x average daily volume. Thus far today, Titan Pharmaceuticals has traded 488,000 shares, vs. average volume of 432,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.3%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.
Titan Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Tue Mar 31, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the fourth quarter and year ended December 31, 2014.
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 25, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Wednesday, April 1, 2014 to discuss the company's financial results as of December 31, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the fourth quarter and full year financial results will be included in a press release to be issued prior to the call.
Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.22 (unch), GSAT: 3.07 (+0.09)
Titan Pharmaceuticals to Present at 27th Annual ROTH Conference
Marketwired - Tue Mar 03, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that Titan President Sunil Bhonsle will present at the 27th annual ROTH Conference on Monday, March 9 at 9:30 a.m. PT at The Ritz-Carlton in Laguna Niguel, Calif.
Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 6.3% (TTNP)
Comtex SmarTrend(R) - Mon Mar 02, 10:08AM CST
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 6.3% to $0.68 on 1.4x average daily volume. Thus far today, Titan Pharmaceuticals has traded 732,000 shares, vs. average volume of 509,000 shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.7%) and outperformed the S&P 500 (6.3% to the S&P's 0.4%) during today's trading.
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.94 (+0.80), ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25), XNPT: 7.60 (+0.17), IPXL: 50.68 (-0.43), ABBV: 62.00 (+1.68), TEVA: 66.37 (-0.77), SNY: 52.35 (+0.48), PRTA: 36.91 (+0.52)
Roth Capital's 4 Reasons To Be Bullish On Titan Pharmaceuticals
TipRanks - at Seeking Alpha - Mon Jan 26, 1:28PM CST
By Sarah Roden Titan Pharmaceuticals ( OTCQB:TTNP ) is a biomedical pharmaceutical company most known for its flagship drug, Probuphine, used to treat opioid addiction. Probuphine has proved to be effective in two clinical studies and one safety...
Titan Pharmaceuticals to Present at 8th Annual OneMedForum
Marketwired - Tue Jan 06, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 8th annual OneMedForum taking place on January 12-13, 2015 in San Francisco. The presentation is scheduled for Jan. 12 at 11 a.m. in the Public Company Track Room, Marriott Marquis, San Francisco, California.
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 50.68 (-0.43), ADMS: 17.94 (+0.80), TEVA: 66.37 (-0.77), ACOR: 34.46 (+0.61), PRTA: 36.91 (+0.52), NDRM: 13.93 (-0.25)
Titan Pharmaceuticals to Present at LD Micro Conference
Marketwired - Mon Dec 01, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 8:30 a.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif.
Enrollment complete in Probuphine Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:03AM CST
Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence
Marketwired - Thu Nov 20, 5:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.
Titan Pharmaceuticals EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:38AM CST
Titan Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Thu Nov 13, 6:02AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the third quarter ended Sept. 30, 2014.
Titan Pharmaceuticals Appoints Two New Board Members
Marketwired - Tue Nov 11, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
CRIS: 2.80 (-0.01)
Titan Pharma reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:12AM CST
